[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Given the clinical picture \u2013 HIV infection with a low CD4 count, neurological symptoms (headaches, blurred vision, confusion, ataxia, memory impairment), CSF findings (lymphocytic pleocytosis, EBV positivity), and MRI findings (solitary, ring-enhancing lesion in the corpus callosum) \u2013 the most likely diagnosis is **Progressive Multifocal Leukoencephalopathy (PML)**.\n\nWhile EBV is often present, it's the reactivation of JC virus in the context of severe immunosuppression that causes PML. The MRI findings are highly suggestive.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "That's a good question to ask when starting a patient on ART.\n\n**Enfuvirtide** is the medication that acts on the gp41 subunit of the HIV envelope glycoprotein. It's a fusion inhibitor.\n\nHowever, it's not typically a first-line agent due to its administration route (subcutaneous injection) and side effect profile. Modern ART regimens generally favor other drug classes.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV-1 detection test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "This patient is most likely in the **acute HIV infection** stage. \n\nHere's why: the recent onset of fever, malaise, diarrhea, and lymphadenopathy are classic symptoms of acute retroviral syndrome, occurring shortly after initial infection. A positive HIV test confirms infection. Importantly, a CD4 count of 650/mm3 is *normal* and indicates the immune system hasn\u2019t been significantly impacted *yet* \u2013 as would be seen in later stages.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9\u00b0F (38.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. What is the mechanism of action of the most appropriate drug for managing this patient\u2019s condition?",
    "answer": "This patient likely has disseminated *Nocardia* infection, given the cavitary lung disease, acid-fast bacilli, and profound immunosuppression. \n\nThe most appropriate drug is **trimethoprim-sulfamethoxazole (TMP-SMX)**.\n\nIts mechanism of action involves sequential blockade of two steps in folate synthesis. Specifically, trimethoprim inhibits dihydrofolate reductase, and sulfamethoxazole inhibits dihydropteroate synthase. *Nocardia* are susceptible because they require folate for survival.",
    "true_answer": "The mechanism of action of the most appropriate drug to manage this patient's condition is inhibition of bacterial folic acid synthesis."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "That's a good research direction. The most likely target would be **the HIV-1 envelope glycoprotein gp120**. \n\nHere's why:\n\n*   **Dominant Target:** gp120 is the primary target for neutralizing antibodies in the natural HIV humoral response. It's exposed on the viral surface and critical for viral entry.\n*   **ELISA/Western Blot:** The antibodies detected by those assays largely recognize gp120 and gp41 (the other envelope protein), but gp120 elicits the stronger, more broadly neutralizing response.\n*   **Potency Focus:** A more potent antibody *against* the natural targets would logically focus on improving the response to the most important one \u2013 gp120.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "That presentation strongly suggests *Aspergillus* species. The fibrocavitary lesion, hemoptysis in an HIV-positive individual, and acute-angle branching septate hyphae on biopsy are classic findings for pulmonary aspergillosis. It's a serious opportunistic infection in this population.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "Given the patient's current ART regimen (zidovudine, lamivudine, dolutegravir) and the addition of valganciclovir, the greatest risk is **myelosuppression**, specifically neutropenia and anemia. \n\nZidovudine *already* carries a risk of these, and valganciclovir can exacerbate it. Close monitoring of his CBC is crucial.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "That's a very common and understandable concern. The most appropriate test immediately after delivery is **HIV-1 DNA PCR (polymerase chain reaction)**. \n\nHere\u2019s why:\n\n*   **Early Detection:** It detects the virus itself, not antibodies. Maternal antibodies cross the placenta, so an antibody test on the newborn wouldn't tell you if the baby is *actually* infected.\n*   **Sensitivity:** DNA PCR is very sensitive and can detect even small amounts of the virus.\n*   **Timing:** It can be done within the first 24-48 hours of life, though later testing is also done to confirm.\n\nLet me know if you'd like to discuss the full management plan for this patient, including maternal ART and infant prophylaxis.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "This is a complex ethical and legal situation. The most appropriate next step is **to strongly counsel the patient about the legal and ethical obligations regarding partner notification, and the potential legal ramifications of not disclosing his HIV status to his wife, who is also a patient.**\n\nHere's why, and what follows:\n\n*   **Dual Relationship:** You have a physician-patient relationship with both individuals, creating a conflict of interest.\n*   **Duty to Warn/Protect:** Many jurisdictions have laws regarding the duty to warn potential partners of a communicable disease like HIV. Even without specific laws, there's an ethical obligation to prevent harm.\n*   **Patient Confidentiality vs. Public Health:** While patient confidentiality is paramount, it is *not* absolute, particularly when public health (or in this case, an individual's health) is at risk.\n*   **Legal Risks:** The patient could face criminal charges for knowingly exposing his wife to HIV.\n\n**Do NOT directly disclose to the wife.** That would be a breach of confidentiality with the patient *and* could create legal issues. \n\nInstead:\n\n1.  **Reiterate Confidentiality Limits:** Explain to the patient that while you respect his desire for privacy, you have legal and ethical obligations.\n2.  **Encourage Voluntary Disclosure:** Strongly urge him to disclose to his wife himself. Offer assistance with how to have that conversation.\n3.  **Discuss Partner Notification Services:** Inform him about local or state partner notification programs, where trained professionals can confidentially notify partners.\n4.  **Legal Consultation:** Suggest the patient seek legal counsel to understand his rights and obligations.\n5.  **Document Everything:** Thoroughly document all counseling and discussions in the patient's chart.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Given the clinical presentation \u2013 acute epigastric pain radiating to the back, nausea, vomiting, elevated amylase and lipase, and CT findings of pancreatitis \u2013 the most likely etiology is **acute pancreatitis**. \n\nWhile her HIV infection is part of her history, it\u2019s less directly linked to *acute* pancreatitis unless there are specific opportunistic infections or medication side effects at play (which aren\u2019t immediately suggested here). Diabetes is a risk factor, as is moderate alcohol use. We need to determine which of those, or another cause, is most likely.",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " A 28-year-old primigravid woman at 38 weeks' gestation is brought to the emergency department in active labor. She has not had regular prenatal care. She has a history of HIV infection but is not currently on antiretroviral therapy. Her previous viral load is unknown. Treatment with intravenous zidovudine is begun to reduce perinatal transmission of the virus. What biological process is most likely disrupted by this drug\u2019s action mechanism?",
    "answer": "That's a good question for a learner. Zidovudine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI). Therefore, it primarily disrupts **reverse transcription** \u2013 the process by which HIV converts its RNA genome into DNA. \n\nEssentially, AZT acts as a faulty building block, halting the creation of viral DNA.",
    "true_answer": " Zidovudine affects elongation of viral DNA by inhibiting the viral reverse transcriptase enzyme."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "That's a good question, reflecting a growing area of research. Here's a brief overview:\n\n**Latent HIV-1:** Studies show distinct DNA methylation patterns in latently infected cells compared to uninfected cells. Generally, there's *hypermethylation* of the HIV-1 provirus in these reservoirs, contributing to transcriptional silencing. This isn't absolute, and some degree of demethylation can be seen, potentially contributing to viral persistence.\n\n**Active Infection:** Active HIV-1 infection is associated with *hypomethylation* of the HIV-1 provirus, allowing for increased viral gene expression. However, the picture is complex \u2013 host cell genes involved in immune function also show altered methylation.\n\nEssentially, methylation is a key epigenetic mechanism influencing HIV persistence and disease progression. It\u2019s an active area of study for potential therapeutic targets (\"kick and kill\" strategies).",
    "true_answer": "DNA methylation is correlated with and functionally linked to HIV-1 pathogenesis and latency. In active infection, HIV-1 infection is associated with global changes in host cell DNA methylation patterns, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]